Demographic
|
Male, n (%)
|
112 (53.8)
|
150 (53.0)
|
0.853
| | | | |
Age, mean ± SD
|
60.8 ± 16.7
|
60.5 ± 16.3
|
0.836
| | | | |
Total hospital stay, days (median, IQR)
|
19 (11–28)
|
18 (11–37)
|
0.188
| | | | |
Hospital stay before BSI, days (median, IQR)
|
3 (0–13)
|
4 (1–14)
|
0.336
| | | | |
ICU stay prior to BSIa
|
11 (5.3)
|
25 (8.8)
|
0.136
| | | | |
Preexisting medical conditions
|
Hypertension
|
58 (27.9)
|
80 (28.3)
|
0.925
| | | | |
Diabetes
|
34 (16.4)
|
45 (15.9)
|
0.876
| | | | |
Lung disease
|
2 (1.0)
|
6 (2.1)
|
0.477
| | | | |
Cardiovascular diseases
|
4 (1.9)
|
7 (2.5)
|
0.921
| | | | |
Hepatobiliary disease
|
59 (28.4)
|
78 (27.6)
|
0.844
| | | | |
Urinary system disease
|
15 (7.2)
|
25 (8.8)
|
0.516
| | | | |
Nervous system disease
|
7 (3.4)
|
8 (2.8)
|
0.732
| | | | |
Malignant solid tumor
|
43 (20.7)
|
63 (22.3)
|
0.673
| | | | |
Hematological Disease
|
39 (18.8)
|
35 (12.4)
|
0.051
| | | | |
Charlson comorbidity score c (median, IQR)
|
2 (0–2)
|
2 (0–2)
|
0.168
| | | | |
Likely source of BSI
|
Central vein Catheter-related infections
|
7.2 (7.2)
|
10 (3.5)
|
0.067
| | | | |
Lung infection
|
52 (25.0)
|
56 (19.8)
|
0.168
| | | | |
Abdominal infection
|
108 (51.9)
|
141 (49.8)
|
0.646
| | | | |
Urinary infection
|
26 (12.5)
|
58 (20.5)
|
0.020
|
0.014
|
1.897
|
1.138
|
3.164
|
Intracranial infection
|
1 (0.5)
|
4 (1.4)
|
0.402
| | | | |
Skin infection
|
6 (2.9)
|
11(3.9)
|
0.548
| | | | |
Primary bloodstream infection
|
19 (9.1)
|
26 (9.2)
|
0.984
| | | | |
Nosocomial-acquired infection
|
124 (59.6)
|
180 (63.6)
|
0.368
| | | | |
Hospitalization prior to BSIb
|
75 (56.0)
|
110 (59.1)
|
0.571
| | | | |
Surgery prior to BSIa
|
27 (13.0)
|
56 (19.8)
|
0.047
| | | | |
Invasive procedure and/or devices prior to BSIa
|
46 (22.1)
|
83 (29.3)
|
0.073
| | | | |
Mechanical ventilation
|
7 (3.4)
|
11 (3.9)
|
0.761
| | | | |
Central venous catheterization
|
20 (9.6)
|
42 (14.8)
|
0.085
| | | | |
Urinary catheterization
|
18 (8.7)
|
42 (14.8)
|
0.039
| | | | |
Gastric catheterization
|
10 (4.8)
|
31(11.0)
|
0.015
| | | | |
Percutaneous catheterization
|
6 (2.9)
|
21 (7.4)
|
0.029
|
0.101
|
2.218
|
0.857
|
5.742
|
Hemodialysis prior to BSIa
|
6 (2.9)
|
3 (1.1)
|
0.251
| | | | |
Chemotherapy or radiotherapy prior to BSIa
|
38 (18.3)
|
39 (13.8)
|
0.177
| | | | |
Corticosteroid use prior to BSIa
|
15 (7.2)
|
21 (7.4)
|
0.930
| | | | |
Immunosuppressant use prior to BSIa
|
1 (0.5)
|
2 (0.7)
|
> 0.050
| | | | |
Antibiotics use prior to BSIa
|
68 (32.7)
|
134 (47.3)
|
0.001
| | | | |
Cepholosporins
|
10 (4.8)
|
38 (13.4)
|
0.001
|
0.007
|
2.767
|
1.325
|
5.779
|
BLBLI combination antibiotics
|
26 (12.5)
|
62 (21.9)
|
0.007
|
0.010
|
1.950
|
1.173
|
3.241
|
Tigecycline
|
2 (1.0)
|
3 (1.1)
|
> 0.050
| | | | |
Carbapenems
|
17 (8.2)
|
20 (7.1)
|
0.646
| | | | |
Aminoglycosides
|
1 (0.5)
|
2 (0.7)
|
> 0.050
| | | | |
Quinolones
|
26 (12.5)
|
36 (12.7)
|
0.942
| | | | |
Laboratory examination
|
White blood cell
|
8.1 (3.8–13.0)
|
9.6 (5.5–14.8)
|
0.045
| | | | |
Platelet (median, IQR)
|
104 (42–183)
|
117 (58–192)
|
0.161
| | | | |
Serum total protein (median, IQR)
|
57.7 (52.0–64.7)
|
58.3 (52.3–64.3)
|
0.949
| | | | |
Severity of illness
|
APACHEII score (median, IQR)
|
9 (6–12)
|
9 (6–13)
|
0.540
| | | | |
Appropriate empirical treatment after BSI
|
200 (96.2)
|
249 (88.3)
|
0.001
| | | | |
Appropriate definitive treatments after BSI
|
204 (98.1)
|
267 (94.3)
|
0.039
| | | | |
7-day mortality
|
17 (8.2)
|
24 (8.1)
|
0.985
| | | | |
14-day mortality
|
23 (11.1)
|
28 (9.9)
|
0.676
| | | | |
28-day mortality
|
29 (13.9)
|
42 (14.8)
|
0.780
| | | | |